Pharmagreen Biotech Stock Fundamentals
| PHBI Stock | USD 0 0.0001 5.88% |
Pharmagreen Biotech fundamentals help investors to digest information that contributes to Pharmagreen Biotech's financial success or failures. It also enables traders to predict the movement of Pharmagreen Pink Sheet. The fundamental analysis module provides a way to measure Pharmagreen Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharmagreen Biotech pink sheet.
Pharmagreen |
Pharmagreen Biotech Company Return On Asset Analysis
Pharmagreen Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Pharmagreen Biotech Return On Asset | -2.3 |
Most of Pharmagreen Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharmagreen Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Pharmagreen Biotech has a Return On Asset of -2.2974. This is 73.74% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is notably higher than that of the company.
Pharmagreen Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pharmagreen Biotech's current stock value. Our valuation model uses many indicators to compare Pharmagreen Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharmagreen Biotech competition to find correlations between indicators driving Pharmagreen Biotech's intrinsic value. More Info.Pharmagreen Biotech is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Pharmagreen Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Pharmagreen Biotech's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Pharmagreen Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharmagreen Biotech's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pharmagreen Biotech could also be used in its relative valuation, which is a method of valuing Pharmagreen Biotech by comparing valuation metrics of similar companies.Pharmagreen Biotech is currently under evaluation in return on asset category among its peers.
Pharmagreen Fundamentals
| Return On Asset | -2.3 | |||
| Current Valuation | 3.12 M | |||
| Shares Outstanding | 454.76 M | |||
| Shares Owned By Insiders | 18.63 % | |||
| EBITDA | (828.26 K) | |||
| Net Income | (875.48 K) | |||
| Cash And Equivalents | 24.26 K | |||
| Total Debt | 119.47 K | |||
| Current Ratio | 0.10 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (426.57 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 1.44 | |||
| Market Capitalization | 2.96 M | |||
| Total Asset | 208.97 K | |||
| Z Score | 4.5 | |||
| Net Asset | 208.97 K |
About Pharmagreen Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmagreen Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmagreen Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmagreen Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Pharmagreen Biotech Inc., a biotech sciences solutions company, focuses on the production of starter plantlets for CBD hemp and medical cannabis industries. The company was incorporated in 2007 and is headquartered in Coquitlam, Canada. Pharmagreen Biotech is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Pharmagreen Pink Sheet
Pharmagreen Biotech financial ratios help investors to determine whether Pharmagreen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmagreen with respect to the benefits of owning Pharmagreen Biotech security.